Drug Profile
OP 101
Alternative Names: Dendrimer N-acetyl-cysteine; OP-101Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator Ashvattha Therapeutics
- Developer Orpheris
- Class Amines; Anti-inflammatories; Antiparkinsonians; Neuroprotectants
- Mechanism of Action I-kappa B kinase inhibitors; Janus kinase inhibitors; MAP kinase kinase kinase inhibitors; NF kappa B kinase inhibitors; Nuclear importation inhibitors; Oxygen radical scavengers; STAT transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II COVID 2019 infections
- No development reported Adrenoleucodystrophy; Neurological disorders; Parkinson's disease
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (IV)
- 28 Apr 2023 No recent reports of development identified for phase-I development in Adrenoleucodystrophy(In volunteers) in Australia (SC)
- 12 Aug 2022 Ashvattha Therapeutics terminates phase II trial in COVID-2019 infections in USA (IV) due to lack of enrollment (NCT04458298)